Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation

https://doi.org/10.1016/j.amjcard.2004.04.060Get rights and content

Abstract

B-type natriuretic peptide (BNP) has emerged as an important marker of ventricular wall stress and is predictive of hemodynamic abnormalities in heart transplantation despite “preserved” systolic function. We evaluated the capacity of BNP to predict deaths due to allograft failure in 62 patients long after heart transplantation (mean 5 ± 2.5 years). Based on the median tendency of measurement of BNP in the absence of rejection during stable surveillance, 2 distinct patient groups were identified as having low BNP (n = 39, <250 pg/ml; median BNP 70 pg/ml) and high BNP (n = 23, ≥250 pg/ml; median BNP 592 pg/ml). No differences between the 2 BNP groups were noted with regard to age, gender, race, time after transplantation, diabetes mellitus, hypertension, and hyperlipidemia with measurement of BNP. Multivariable analysis showed that decreased left ventricular ejection fraction, angiographic coronary artery disease, and increased serum creatinine were independent predictors of elevated BNP. Cardiac deaths were significantly greater in those with high BNP levels (35%) than in those with low BNP (2.5%, p = 0.01). Absence of significant angiographic coronary artery disease coupled with a BNP of <250 pg/ml was associated with the lowest event rate (0%), whereas patients with coronary artery disease and BNP ≥250 pg/ml exhibited a 50% cardiac death rate (p <0.01 for trend). Cox's model confirmed that increased BNP and decreased left ventricular ejection fraction are independent predictors of poor survival. Survival analysis associated lower BNP levels with an excellent long-term survival rate (95%) and higher BNP levels with a markedly decreased survival rate (60%, p = 0.002). Higher BNP levels in patients long after heart transplantation are associated with allograft dysfunction and cardiac allograft vasculopathy and are strongly and independently predictive of cardiovascular death.

Section snippets

Study design

We examined 66 consecutive adult patients who underwent primary heart transplantation and who were stable beyond the first year. At the time of inclusion into the study, patients could not have evidence of ongoing allograft rejection, severe allograft dysfunction (defined as left ventricular ejection fraction [LVEF] <0.30), or angiographic coronary artery disease. Four patients were excluded due to inadequate follow-up (lost to follow-up) or end-stage renal disease that required dialysis

Baseline characteristics

Of 62 heart transplant recipients, 39 had low levels of BNP (<250 pg/ml) and 23 exhibited high levels of BNP (≥250 pg/ml). Median levels of BNP in the 2 groups were 70 pg/ml (range 7 to 209) and 592 pg/ml (range 268 to 3,800), respectively (p <0.0001). Thus, the cutpoints developed provided robust discrimination of BNP levels. There were no significant differences with regard to recipient's age, gender, race, and years after transplantation. Similarly, no differences in metabolic variables,

Discussion

This investigation found an important prognostic relation of high BNP levels with cardiac outcomes in patients long after heart transplantation. BNP, a marker of allograft function, was closely related to allograft failure and development of cardiac allograft vasculopathy and may serve as an important marker for likelihood of cardiac death. Because BNP reflects ventricular wall stress and pressure, levels of this hormone in recipients of heart transplants have been studied as an indicator of

References (8)

There are more references available in the full text version of this article.

Cited by (0)

View full text
Copyright © 2004 Excerpta Medica Inc. All rights reserved.